Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class ASSE: 688621

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BTP0427

Sep 17, 2026 · Issued by Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Sep 17, 2026

Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BTP0427

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class A

"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Progress of Cooperative Investment with Private FundSep 15
"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on the Use of Certain Raised Funds to Increase the Capital of a Wholly-owned Subsidiary for the Implementation of Fundraising Investment ProjectsAug 29
"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Vesting Results for the 1st Vesting Period of the Initial Grant under the 2025 Restricted Share Incentive PlanAug 13
"Beijing Sun-Novo Pharmaceutical Research Co., Ltd."Announcement on Voluntary Disclosure of External InvestmentJul 29

All Beijing Sun-novo Pharmaceutical Research Co. Ltd. Class A news releases